45 related articles for article (PubMed ID: 18772231)
1. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
[TBL] [Abstract][Full Text] [Related]
2. Dual roles of QOA-8a in antiosteoporosis: a combination of bone anabolic and anti-resorptive effects.
Wu J; Shen Q; Cui W; Zhao Y; Huai Y; Zhang YC; Bao BH; Liu CX; Jiang Q; Li JX
Acta Pharmacol Sin; 2018 Feb; 39(2):230-242. PubMed ID: 28816232
[TBL] [Abstract][Full Text] [Related]
3. Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis.
Sinder BP; Zweifler L; Koh AJ; Michalski MN; Hofbauer LC; Aguirre JI; Roca H; McCauley LK
J Bone Miner Res; 2017 Oct; 32(10):2116-2127. PubMed ID: 28600866
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine and a low activity bisphosphonate conjugate prevent and reverse ovariectomy-induced bone loss in mice through dual antiresorptive and anabolic effects.
Yao Z; Ayoub A; Srinivasan V; Wu J; Tang C; Duan R; Milosavljevic A; Ebetino F; Frontier A; Boyce B
Res Sq; 2024 May; ():. PubMed ID: 38746138
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.
Wu X; Pang L; Lei W; Lu W; Li J; Li Z; Frassica FJ; Chen X; Wan M; Cao X
Cell Stem Cell; 2010 Nov; 7(5):571-80. PubMed ID: 21040899
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.
Kawatani M; Osada H
Cancer Sci; 2009 Nov; 100(11):1999-2005. PubMed ID: 19673888
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-3 enhances anabolic bone formation through WNT signaling.
Johnson de Sousa Brito FM; Butcher A; Pisconti A; Poulet B; Prior A; Charlesworth G; Sperinck C; Scotto di Mase M; Liu K; Bou-Gharios G; Jurgen van 't Hof R; Daroszewska A
FASEB J; 2021 Apr; 35(4):e21246. PubMed ID: 33769615
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
9. Antiosteoporotic Effects of Huangqi Sanxian Decoction in Cultured Rat Osteoblasts by Proteomic Characterization of the Target and Mechanism.
Guo CC; Zheng LH; Fu JY; Zhu JH; Zhou YX; Zeng T; Zhou ZK
Evid Based Complement Alternat Med; 2015; 2015():514063. PubMed ID: 26557149
[TBL] [Abstract][Full Text] [Related]
10. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.
Hayden RS; Vollrath M; Kaplan DL
Acta Biomater; 2014 Jan; 10(1):486-93. PubMed ID: 24096150
[TBL] [Abstract][Full Text] [Related]
11. A Special Ingredient (VtR) Containing Oligostilbenes Isolated from Vitis thunbergii Prevents Bone Loss in Ovariectomized Mice: In Vitro and In Vivo Study.
Huang YL; Liu YW; Huang YJ; Chiou WF
Evid Based Complement Alternat Med; 2013; 2013():409421. PubMed ID: 23662133
[TBL] [Abstract][Full Text] [Related]
12. Mechanical stimulation and intermittent parathyroid hormone treatment induce disproportional osteogenic, geometric, and biomechanical effects in growing mouse bone.
McAteer ME; Niziolek PJ; Ellis SN; Alge DL; Robling AG
Calcif Tissue Int; 2010 May; 86(5):389-96. PubMed ID: 20306026
[TBL] [Abstract][Full Text] [Related]
13. Identification of biphenylcarboxylic acid derivatives as a novel class of bone resorption inhibitors.
Van 't Hof RJ; Idris AI; Ridge SA; Dunford J; Greig IR; Ralston SH
J Bone Miner Res; 2004 Oct; 19(10):1651-60. PubMed ID: 15355560
[TBL] [Abstract][Full Text] [Related]
14. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
16. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Sims NA; Ng KW
Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
[TBL] [Abstract][Full Text] [Related]
17. [A Novel Oral Anti-osteoporosis Drug with Osteogenesis-promoting Effects via Osteoblast Differentiation].
Kitao T; Ito Y; Fukui M; Yamamoto M; Shoji Y; Takeda S; Shirahase H
Yakugaku Zasshi; 2019; 139(1):19-25. PubMed ID: 30606923
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation.
Idris AI; Greig IR; Bassonga-Landao E; Ralston SH; van 't Hof RJ
Endocrinology; 2009 Jan; 150(1):5-13. PubMed ID: 18772231
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
